# EDGAR Filing Document

**Accession Number:** 0001610618
**File Stem:** 0001193125-26-005807
**Filing Date:** 2026-1
**Character Count:** 11860
**Document Hash:** 9d7c6f223ded4705409cf2fc7da80165
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-005807.hdr.sgml**: 20260107

**ACCESSION NUMBER**: 0001193125-26-005807

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260107

**DATE AS OF CHANGE**: 20260107

**EFFECTIVENESS DATE**: 20260107

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cidara Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001610618
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 461537286
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-281523
- **FILM NUMBER:** 26514652

**BUSINESS ADDRESS:**
- **STREET 1:** 6310 NANCY RIDGE DRIVE
- **STREET 2:** SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-752-6170

**MAIL ADDRESS:**
- **STREET 1:** 6310 NANCY RIDGE DRIVE
- **STREET 2:** SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** K2 THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20140611

**As filed with the Securities and Exchange Commission on January 7, 2026** 

**Registration No. 333-289363** 

**Registration No. 333-285607** 

**Registration No. 333-281523** 

**Registration No. 333-278872** 

**Registration No. 333-270781** 

**Registration No. 333-263350** 

**Registration No. 333-259219** 

**Registration No. 333-253545** 

**Registration No. 333-236874** 

**Registration No. 333-231326** 

**Registration No. 333-228282** 

**Registration No. 333-216722** 

**Registration No. 333-210263** 

**Registration No. 333-203434** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**POST-EFFECTIVE AMENDMENT NO. 1** 

**TO** 

**Form S-8 Registration Statement No. 333-289363** 

**Form S-8 Registration Statement No. 333-285607** 

**Form S-8 Registration Statement No. 333-281523** 

**Form S-8 Registration Statement No. 333-278872** 

**Form S-8 Registration Statement No. 333-270781** 

**Form S-8 Registration Statement No. 333-263350** 

**Form S-8 Registration Statement No. 333-259219** 

**Form S-8 Registration Statement No. 333-253545** 

**Form S-8 Registration Statement No. 333-236874** 

**Form S-8 Registration Statement No. 333-231326** 

**Form S-8 Registration Statement No. 333-228282** 

**Form S-8 Registration Statement No. 333-216722** 

**Form S-8 Registration Statement No. 333-210263** 

**Form S-8 Registration Statement No. 333-203434** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## CIDARA THERAPEUTICS, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **46-1537286** |
| **(State or other jurisdiction of incorporation)** | **(I.R.S. Employer Identification Number)** |

---

**2013 Stock Option and Grant Plan** 

**2015 Equity Incentive Plan** 

**2015 Employee Stock Purchase Plan** 

**2020 Inducement Incentive Plan** 

**2024 Equity Incentive Plan** 

**(Full title of the plan)** 

**Kelly E.W. Grez** 

**Secretary** 

**6310 Nancy Ridge Drive, Suite 101** 

**San Diego, California 92121** 

**(858) 752-6170** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copy to:***

**Saee Muzumdar** 

**Sebastian L. Fain** 

**Gibson, Dunn & Crutcher LLP** 

**200 Park Avenue New York, NY 10166** 

**(212) 351-4035** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated Filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**<u>DEREGISTRATION OF SECURITIES</u>**

These Post-Effective Amendments (these "Post-Effective Amendments") relate to the following Registration Statements on Form S-8 (the "Registration Statements") filed by Cidara Therapeutics, Inc., a Delaware corporation (the "Company"), with the Securities and Exchange Commission:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. [333-289363](http://www.sec.gov/Archives/edgar/data/1610618/000161061825000082/cdtxs-82025x08x07.htm) , filed on August 7, 2025, registering 2,880,000 shares of common stock under the
Company's 2024 Equity Incentive Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. [333-285607](http://www.sec.gov/Archives/edgar/data/1610618/000161061825000020/cdtxs-82025x03x06.htm) , filed on March 6, 2025, registering 24,516 shares of common stock under the Company's
2015 Employee Stock Purchase Plan and 350,000 shares of common stock under the Company's 2020 Inducement Incentive Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. [333-281523](http://www.sec.gov/Archives/edgar/data/1610618/000161061824000119/cdtxs-82024x08x13.htm) , filed on August 13, 2024, registering 3,225,586 shares of common stock under the
Company's 2024 Equity Incentive Plan and 225,000 shares of common stock under the Company's 2020 Inducement Incentive Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. [333-278872](http://www.sec.gov/Archives/edgar/data/1610618/000161061824000046/cdtxs-82024x04x22.htm) , filed on April 23, 2024, registering 3,624,079 shares of common stock under the
Company's 2015 Equity Incentive Plan and 490,336 shares of common stock under the Company's 2015 Employee Stock Purchase Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. [333-270781](http://www.sec.gov/Archives/edgar/data/1610618/000161061823000024/cdtxs-82023x03x23.htm) , filed on March 23, 2023, registering 2,898,337 shares of common stock under the
Company's 2015 Equity Incentive Plan and 490,336 shares of common stock under the Company's 2015 Employee Stock Purchase Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. [333-263350](http://www.sec.gov/Archives/edgar/data/1610618/000161061822000011/cdtxs-82022x03x07.htm) , filed on March 7, 2022, registering 2,714,546 shares of common stock under the
Company's 2015 Equity Incentive Plan and 490,336 shares of common stock under the Company's 2015 Employee Stock Purchase Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. [333-259219](http://www.sec.gov/Archives/edgar/data/1610618/000161061821000074/cdtxs-82021x08x31.htm) , filed on August 31, 2021, registering 625,000 shares of common stock under the
Company's 2020 Inducement Incentive Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. [333-253545](http://www.sec.gov/Archives/edgar/data/1610618/000161061821000012/cdtxs-82021x02x25.htm) , filed on February 25, 2021, registering 1,791,653 shares of common stock under the
Company's 2015 Equity Incentive Plan, 447,913 shares of common stock under the Company's 2015 Employee Stock Purchase Plan, and 750,000 shares of common stock under the Company's 2020 Inducement Incentive Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. [333-236874](http://www.sec.gov/Archives/edgar/data/1610618/000161061820000012/cdtxs-82020x03x03.htm) , filed on March 4, 2020, registering 1,353,539 shares of common stock under the
Company's 2015 Equity Incentive Plan and 338,384 shares of common stock under the Company's 2015 Employee Stock Purchase Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. [333-231326](http://www.sec.gov/Archives/edgar/data/1610618/000161061819000036/cdtxs-82019x05x09.htm) , filed on May 9, 2019, registering 1,112,640 shares of common stock under the
Company's 2015 Equity Incentive Plan and 278,160 shares of common stock under the Company's 2015 Employee Stock Purchase Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. [333-228282](http://www.sec.gov/Archives/edgar/data/1610618/000161061818000111/cdtxs-82018x11x08.htm) , filed on November 8, 2018, registering 821,095 shares of common stock under the
Company's 2015 Equity Incentive Plan and 205,273 shares of common stock under the Company's 2015 Employee Stock Purchase Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. [333-216722](http://www.sec.gov/Archives/edgar/data/1610618/000161061817000015/cdtxs-82017x03x15.htm) , filed on March 15, 2017, registering 673,485 shares of common stock under the
Company's 2015 Equity Incentive Plan and 168,371 shares of common stock under the Company's 2015 Employee Stock Purchase Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. [333-210263](http://www.sec.gov/Archives/edgar/data/1610618/000156459016015008/cdtx-s8_20160317.htm) , filed on March 18, 2016, registering 557,700 shares of common stock under the
Company's 2015 Equity Incentive Plan and 139,425 shares of common stock under the Company's 2015 Employee Stock Purchase Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. [333-203434](http://www.sec.gov/Archives/edgar/data/1610618/000119312515131339/d909250ds8.htm) , filed on April 15, 2015, registering 1,416,778 shares of common stock under the Company's 2013 Stock Option and Grant Plan, 3,258,922 shares of common stock under the Company's 2015
Equity Incentive Plan, and 245,168 shares of common stock under the Company's 2015 Employee Stock Purchase Plan.

Pursuant to the Agreement and Plan of Merger, dated as of November 13, 2025 (the "Merger Agreement"), by and among the Company, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Caymus Purchaser, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company continuing as the surviving corporation and a direct wholly owned subsidiary of Parent. As a result of the transactions contemplated by the Merger Agreement, the Company has terminated all offerings of its securities pursuant to the Registration Statements and hereby removes and withdraws from registration all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Rahway, in the State of New Jersey, on this 7th day of January, 2026.

---

| | |
|:---|:---|
| **CIDARA THERAPEUTICS, INC. (REGISTRANT)** | **CIDARA THERAPEUTICS, INC. (REGISTRANT)** |
| By: | /s/ Kelly E.W. Grez |
| Name: | Kelly E.W. Grez |
| Title: | Secretary |

---

Pursuant to Rule 478 of the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments to the Registration Statements.